Data-Driven Assessment of the Association of Polymorphisms in 5-Fluorouracil Metabolism Genes with Outcome in Adjuvant Treatment of Colorectal Cancer-Reference-Cited by-同舟云学术

Data-Driven Assessment of the Association of Polymorphisms in 5-Fluorouracil Metabolism Genes with Outcome in Adjuvant Treatment of Colorectal Cancer

Published:2012-04 Issue: Volume: Page:n/a-n/a
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Sarac Sinan B.,Rasmussen Christian H.,Afzal Shoaib¹,Thirstrup Steffen²,Jensen Søren A.³,Colding-Jørgensen Morten⁴,Poulsen Henrik E.,Mosekilde Erik⁵

Affiliation:

1. Department of Clinical Biochemistry; Herlev Hospital; Herlev; Denmark

2. Danish Medicines Agency; Copenhagen; Denmark

3. Department of Oncology; Herlev Hospital; Herlev; Denmark

4. Novo Nordisk A/S; Bagsvaerd; Denmark

5. Department of Physics; Technical University of Denmark; Lyngby; Denmark

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Reference45 articles.

1. The Council for International Organizations of Medical Sciences (CIOMS) Working CIOMS group IV - benefit-risk balance for marketed drugs: evaluating safety signals [online] http://www.cioms.ch/publications/g4-benefit-risk.pdf

2. US Food and Drug Administration (FDA) The future of drug safety - promoting and protecting the health of the public [online] http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM171627.pdf

3. Committee for Medicinal Products for Human Use (CHMP) Report of the CHMP working group on benefit-risk assessment models and methods http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069634.pdf

4. Measuring Benefit and Balancing Risk: Strategies for the benefit-risk assessment of new medicines in a risk-averse environment Washington, DC, US: 19-20 June 2008 http://www.cmr.org

5. Strategies for Communicating Benefit-Risk to Decision Makers: Explaining Methods, Findings and Conclusions Through a Common Approach Washington, DC, US: 17-19 June 2009 http://www.cmr.org/workshops

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multifactor dimensionality reduction method identifies novel SNP interactions in the WNT protein interaction networks that are associated with recurrence risk in colorectal cancer;Frontiers in Oncology;2023-03-14

2. Examining SNP-SNP interactions and risk of clinical outcomes in colorectal cancer using multifactor dimensionality reduction based methods;Frontiers in Genetics;2022-08-03

3. Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy;Drug Resistance Updates;2015-05